Investigating the gut microbiome's role in antibiotic-resistant infections after lung or liver transplants
The Gut Microbiome in Carbapenem-Resistant Enterobacteriaceae Colonization, Persistence, Infection, and Tolerance after Lung or Liver Transplantation
This study is looking at how the bacteria in your gut might affect the presence of tough-to-treat infections in people who have had lung or liver transplants, with the goal of finding ways to better manage antibiotic resistance for these patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11006352 on NIH RePORTER |
What this research studies
This research focuses on understanding how the gut microbiome influences the colonization and persistence of carbapenem-resistant Enterobacteriaceae (CRE) in patients who have undergone lung or liver transplantation. The study aims to identify genetic traits of CRE that contribute to infections and tolerance to antibiotics, as well as the gut microbiota changes associated with these conditions. By analyzing stool samples and patient data, researchers hope to uncover patterns that could lead to better management of antibiotic resistance in transplant recipients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have received a lung or liver transplant and are at risk for infections caused by carbapenem-resistant bacteria.
Not a fit: Patients who have not undergone lung or liver transplantation or those without risk factors for CRE infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing and treating antibiotic-resistant infections in transplant patients.
How similar studies have performed: Previous research has shown promising results in understanding the gut microbiome's role in antibiotic resistance, suggesting that this approach could yield valuable insights.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Haidar, Ghady — University of Pittsburgh at Pittsburgh
- Study coordinator: Haidar, Ghady
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.